Tilray Brands, Inc. Overview
Company Headquarter: Ontario, Canada
Founded: 2013
Workforce: ~1800
Company Working: Tilray Brands, Inc. (Tilray) engages in the research, cultivation, production, and distribution of medical cannabis and cannabinoids. The company is focusing on medical cannabis research, cultivation, processing, and distribution of cannabis products worldwide. Its products include dried cannabis and cannabis extracts. It operates through the following segments: cannabis and hemp. The cannabis segment sales consist of adult-use, medical, and bulk sales of cannabis under-regulated licenses and sold to retail, wholesale, pharmacy, government, and direct to the patient. The hemp segment sales consist of hemp seed, hemp foods, board spectrum hemp extract containing CBD sold in an unlicensed operation and sold to retail, wholesale, and direct to consumers. It is a GMP-certified medical cannabis producer, which supplies cannabis flower and extract products to tens of thousands of patients, physicians, pharmacies, hospitals, governments, and researchers on five continents. Its subsidiaries include Manitoba Harvest (Canada), High Park Company (Canada), Tilray Australia & New Zealand, Tilray Canada, Tilray Europe, and Tilray Latin Americas. In 2018, the company created a Medical Advisory Board, which guides its clinical trial selection process and product development initiatives. It has seven production and processing facilities, including one in Portugal, three cultivation sites in Ontario & British Columbia, and three processing facilities in Manitoba & Ontario. In May 2021, Tilray and Aphria Inc. (Canada) announced their merger in an all-stock deal.
The company is directly present in more than 10 countries and has a strong presence in all the established markets such as North Americas, Europe, Africa, and Australia. It also focuses on the research and development of innovative products and spends a significant amount of revenue on R&D
Strategy
Tilray's strategy to focus on international expansion. The Canadian cannabis producer reported better-than-expected sales but missed on the bottom line due to a lack of supply in Canada and high international expansion costs. Tilray is focusing its strategy on consumer products and medicinal markets by collaborating with pharmaceutical giants for clinical trials across the globe. Its recent mergers and acquisitions are anticipated to increase the availability of cash flow further fueling expansive strategies.
